228 related articles for article (PubMed ID: 32034082)
21. A mouse mutant deficient in both neuronal ceroid lipofuscinosis-associated proteins CLN3 and TPP1.
Sleat DE; Banach-Petrosky W; Larrimore KE; Nemtsova Y; Wiseman JA; Najafi A; Johnson D; Poole TA; Takahashi K; Cooper JD; Lobel P
J Inherit Metab Dis; 2023 Jul; 46(4):720-734. PubMed ID: 37078466
[TBL] [Abstract][Full Text] [Related]
22. Converging roles of PSENEN/PEN2 and CLN3 in the autophagy-lysosome system.
Klein M; Kaleem A; Oetjen S; Wünkhaus D; Binkle L; Schilling S; Gjorgjieva M; Scholz R; Gruber-Schoffnegger D; Storch S; Kins S; Drewes G; Hoffmeister-Ullerich S; Kuhl D; Hermey G
Autophagy; 2022 Sep; 18(9):2068-2085. PubMed ID: 34964690
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T
Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148
[TBL] [Abstract][Full Text] [Related]
24. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
[TBL] [Abstract][Full Text] [Related]
25. Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update.
Rakheja D; Narayan SB; Bennett MJ
Curr Mol Med; 2007 Sep; 7(6):603-8. PubMed ID: 17896996
[TBL] [Abstract][Full Text] [Related]
26. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL).
Järvelä I; Lehtovirta M; Tikkanen R; Kyttälä A; Jalanko A
Hum Mol Genet; 1999 Jun; 8(6):1091-8. PubMed ID: 10332042
[TBL] [Abstract][Full Text] [Related]
27. The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.
Wibbeler E; Nickel M; Schwering C; Schulz A; Mink JW
Eur J Paediatr Neurol; 2022 May; 38():62-65. PubMed ID: 35427884
[TBL] [Abstract][Full Text] [Related]
28. Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo.
Schultz ML; Tecedor L; Lysenko E; Ramachandran S; Stein CS; Davidson BL
Neurobiol Dis; 2018 Jul; 115():182-193. PubMed ID: 29660499
[TBL] [Abstract][Full Text] [Related]
29. A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes.
Persaud-Sawin DA; McNamara JO; Rylova S; Vandongen A; Boustany RM
Pediatr Res; 2004 Sep; 56(3):449-63. PubMed ID: 15240864
[TBL] [Abstract][Full Text] [Related]
30. Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation.
Calcagni' A; Staiano L; Zampelli N; Minopoli N; Herz NJ; Di Tullio G; Huynh T; Monfregola J; Esposito A; Cirillo C; Bajic A; Zahabiyon M; Curnock R; Polishchuk E; Parkitny L; Medina DL; Pastore N; Cullen PJ; Parenti G; De Matteis MA; Grumati P; Ballabio A
Nat Commun; 2023 Jul; 14(1):3911. PubMed ID: 37400440
[TBL] [Abstract][Full Text] [Related]
31. Neurodevelopmental delay in the Cln3Deltaex7/8 mouse model for Batten disease.
Osório NS; Sampaio-Marques B; Chan CH; Oliveira P; Pearce DA; Sousa N; Rodrigues F
Genes Brain Behav; 2009 Apr; 8(3):337-45. PubMed ID: 19243453
[TBL] [Abstract][Full Text] [Related]
32. Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.
Hersrud SL; Kovács AD; Pearce DA
Biochim Biophys Acta; 2016 Jul; 1862(7):1324-36. PubMed ID: 27101989
[TBL] [Abstract][Full Text] [Related]
33. Altered sensitivity of cerebellar granule cells to glutamate receptor overactivation in the Cln3(Δex7/8)-knock-in mouse model of juvenile neuronal ceroid lipofuscinosis.
Finn R; Kovács AD; Pearce DA
Neurochem Int; 2011 May; 58(6):648-55. PubMed ID: 21315126
[TBL] [Abstract][Full Text] [Related]
34. A novel mutation af Cln3 associated with delayed-classic juvenile ceroid lipofuscinois and autophagic vacuolar myopathy.
Licchetta L; Bisulli F; Fietz M; Valentino ML; Morbin M; Mostacci B; Oliver KL; Berkovic SF; Tinuper P
Eur J Med Genet; 2015 Oct; 58(10):540-4. PubMed ID: 26360874
[TBL] [Abstract][Full Text] [Related]
35. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
[TBL] [Abstract][Full Text] [Related]
36. CLN3 is required for the clearance of glycerophosphodiesters from lysosomes.
Laqtom NN; Dong W; Medoh UN; Cangelosi AL; Dharamdasani V; Chan SH; Kunchok T; Lewis CA; Heinze I; Tang R; Grimm C; Dang Do AN; Porter FD; Ori A; Sabatini DM; Abu-Remaileh M
Nature; 2022 Sep; 609(7929):1005-1011. PubMed ID: 36131016
[TBL] [Abstract][Full Text] [Related]
37. Evidence for aberrant astrocyte hemichannel activity in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL).
Burkovetskaya M; Karpuk N; Xiong J; Bosch M; Boska MD; Takeuchi H; Suzumura A; Kielian T
PLoS One; 2014; 9(4):e95023. PubMed ID: 24736558
[TBL] [Abstract][Full Text] [Related]
38. The CLN3 gene and protein: What we know.
Mirza M; Vainshtein A; DiRonza A; Chandrachud U; Haslett LJ; Palmieri M; Storch S; Groh J; Dobzinski N; Napolitano G; Schmidtke C; Kerkovich DM
Mol Genet Genomic Med; 2019 Dec; 7(12):e859. PubMed ID: 31568712
[TBL] [Abstract][Full Text] [Related]
39. Loss of the Batten disease gene CLN3 prevents exit from the TGN of the mannose 6-phosphate receptor.
Metcalf DJ; Calvi AA; Seaman MNj; Mitchison HM; Cutler DF
Traffic; 2008 Nov; 9(11):1905-14. PubMed ID: 18817525
[TBL] [Abstract][Full Text] [Related]
40. Altered flurothyl seizure induction latency, phenotype, and subsequent mortality in a mouse model of juvenile neuronal ceroid lipofuscinosis/batten disease.
Kriscenski-Perry E; Applegate CD; Serour A; Mhyre TR; Leonardo CC; Pearce DA
Epilepsia; 2002 Oct; 43(10):1137-40. PubMed ID: 12366726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
